Imaging scans to monitor how immunotherapy works in lung cancer

This trial is testing whether a special type of imaging scan called 68Ga-grazytracer PET can help doctors see how well immunotherapy is working in people with stage III non-small-cell lung cancer. The scan detects immune cells that have gathered at the cancer site after treatment. This information could help doctors decide whether to continue with the current treatment plan or make adjustments.

Right now, doctors have limited ways to quickly tell if immunotherapy is actually working against advanced lung cancer. This trial exists to see if the new imaging technique can fill that gap, giving doctors better information sooner so they can make smarter treatment decisions for their patients.